Results 191 to 200 of about 40,413 (292)

Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives. [PDF]

Curr Opin Hematol
Pan L, Zhu J.
europepmc   +1 more source

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 5, May 2026.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications. [PDF]

Front Pharmacol
Yadava S, Dontiboina HR, Dugluri S, Yadagiri G, Choudhury P, Kakarla R.   +5 more
europepmc   +1 more source

TGFβ‐Mediated Overexpression of Podoplanin Serves as a Potential Diagnostic Biomarker in Acute Promyelocytic Leukemia

Molecular Carcinogenesis, Volume 65, Issue 5, Page 556-564, May 2026.
ABSTRACT Early diagnosis of acute promyelocytic leukemia (APL), driven by PML‐RARA oncoprotein, is vital for survival, as delays can cause fatal coagulopathy without prompt therapeutic intervention of all‐trans retinoic acid and arsenic trioxide. Although APL is diagnosed using microscopy, immunophenotyping, and FISH/PCR for PML‐RARA, morphological ...
Akash Maity, Rohit Kumar, Madhavi Dutta, Ansit Mishra, Jitendra Gawde, Jagruti Patil, Darshana Kadam, Sumeet Mirgh, Anant Gokarn, Hasmukh Jain, Lingaraj Nayak, Bhausaheb Bagal, Sachin Punatar, Manju Sengar, Navin Khattry, P. G. Subramanian, Prashant Tembhare, Syed K. Hasan   +17 more
wiley   +1 more source

The key role and research progress of endothelial cells in renal microcirculation. [PDF]

Front Med (Lausanne)
Tang W, Liu H, Li X, Deng S.
europepmc   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic <i>Hareavirales</i>: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses. [PDF]

Viruses
Chaput S, Nougairède A, Touret F.
europepmc   +1 more source

Bleeding Disorders in Children With Genetic Diseases: A Narrative Review

Acta Paediatrica, Volume 115, Issue 5, Page 1015-1024, May 2026.
ABSTRACT Aim The lack of data on bleeding risk assessment in children with genetic diseases is concerning given their increased care needs and risk of haemorrhagic complications compared to the general population. Identification of haemostatic disorders is crucial for implementing preventive measures and mitigating bleeding risk.
Raphaelle Cagol, Mariam Sbeity Barakat, Marjolaine Willems, Tasnime Akbaraly, Biron‐Andreani Christine, Isabelle Diaz, Alexandre Theron   +6 more
wiley   +1 more source

Preparation of cold-stored platelets on-demand: A novel approach to inventory management. [PDF]

Transfusion
Johnson L, Waters L, Roan C, Lei P, Mahajan J, Portier M, Winskel-Wood B, Marks DC.   +7 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source